It was also shown that there was a correlation between PARP2 and BRCA1/2 in the luminal B subgroup, indicating that those breast cancer patients can receive Anti-HER2 Monoclonal Antibodies as therapeutic drugs available in the clinic at present. This evidence concerns the gene BRCA1 and breast carcinoma.